Sorrento Reports Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept; Says Achieving Improvements In Rheumatoid Arthritis Disease Measures At 50% Of Standard Dose For Patients (7 of 7) With Inadequate Response To Subcuta
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements
